Komori
Share Issuance and Disposal4888STELLA PHARMA CORPORATIONPharmaceuticals

Notice of Completion of Payment for New Shares and Stock Acquisition Rights Issued through the Fourth Private Placement under the Share and Stock Acquisition Rights Issuance Program Agreement

For the fourth private placement, payment for the issuance of 1,000,000 new shares and the allocation of 10,500 stock acquisition rights has been completed.

Worth reading
50Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
373000000
JPY (proceeds from issuance of new shares)
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of New Shares and Stock Acquisition Rights through a Private Placement (Fourth Private Placement)

Who receives how much

New shares 1,000,000 common shares / Stock Acquisition Rights 10,500 stock acquisition rights (100 shares per stock acquisition right; 1,050,000 potential shares)

CVI Investments, Inc.1,000,000 new shares and 10,500 stock acquisition rights

The lower thin line represents the existing number of shares to which these shares will be added.

New shares ¥373 per share / Stock Acquisition Rights ¥288 per stock acquisition right
Total issue value

New shares ¥373,000,000 / Stock Acquisition Rights ¥3,024,000

Amount of funds to be raised
New shares: ¥373,000,000. Stock acquisition rights: ¥598,374,000 (¥3,024,000 for issuance of stock acquisition rights and ¥595,350,000 upon exercise). Estimated net proceeds: Not disclosed.
Terms of the stock acquisition rights
Exercise price
¥567 per share. Adjustment provisions and floor price: Not disclosed.
Exercise period
From 5 November 2026 to 4 November 2030
Number of Stock Acquisition Rights
Total number issued: 10,500. Outstanding unexercised balance: Not disclosed.
Payment date
4 November 2026
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of New Shares and Stock Acquisition Rights through a Private Placement (Fourth Private Placement)
Number of shares to be issued or disposed ofNew shares 1,000,000 common shares / Stock Acquisition Rights 10,500 stock acquisition rights (100 shares per stock acquisition right; 1,050,000 potential shares)
Issue price and disposal priceNew shares ¥373 per share / Stock Acquisition Rights ¥288 per stock acquisition right
Total issue valueNew shares ¥373,000,000 / Stock Acquisition Rights ¥3,024,000
Amount of funds to be raisedNew shares: ¥373,000,000. Stock acquisition rights: ¥598,374,000 (¥3,024,000 for issuance of stock acquisition rights and ¥595,350,000 upon exercise). Estimated net proceeds: Not disclosed.
Payment date4 November 2026
Intended allotteeName CVI Investments, Inc. / Number of Shares 1,000,000 new shares and 10,500 stock acquisition rights
Exercise price¥567 per share. Adjustment provisions and floor price: Not disclosed.
Exercise periodFrom 5 November 2026 to 4 November 2030
Number of Stock Acquisition RightsTotal number issued: 10,500. Outstanding unexercised balance: Not disclosed.
Items this document does not state (18)
Estimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The prescribed payment procedures for the fourth private placement announced on 19 October 2026 have been completed.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.